Market Newsdesk

CHARLOTTE, N.C., Feb. 24, 2021 /PRNewswire/ — Nucor Corporation (NYSE: NUE) announced plans today to build a third TrueCore manufacturing facility to be located in Brigham City, Utah. The 120,000 square foot facility will manufacture insulated wall and roof panels using state-of-the-art continuous line equipment. The new facility is expected to be operational in 2022 and will employ 50 teammates.

“We are excited to be building our third TrueCore facility in the last three years. Locating in Utah will give us a national footprint and allow us to competitively service our customers in the western U.S. and Canadian markets,” said Conor Lowery, Director of Operations at TrueCore.

TrueCore produces insulated metal panels that are used as exterior walls, interior partitions, ceilings and roofs in the cold storage, commercial and industrial construction markets. With thicknesses ranging from 2-8 inches and widths up to 44 inches, the company’s panels and facilities are designed to deliver consistent quality as well as reduced lead times.

“Building this third TrueCore facility will greatly expand our capacity and enhance our ability to service our metal building customers. This new facility will further our strategy of growing our line of value-added products for our customers,” said Jeff Carmean, President of Nucor Buildings Group.

In 2019, TrueCore was acquired by Nucor Corporation and is part of the company’s Nucor Buildings Group division. We would like to thank the State of Utah, Box Elder County and the Box Elder County School Board for support of this project, and contingent upon approval and finalization of tax incentives, the TrueCore facility in Brigham City will join the approximately one dozen facilities operated by Nucor, through its divisions, subsidiaries and affiliates in the State of Utah. Nucor employs approximately 1,300 teammates in Utah and has been a member of the state’s business community since 1979, when the company began building its scrap-based steel bar mill located in Plymouth.

Nucor produces metal buildings and components throughout the United States under the following brands: Nucor Building Systems, American Buildings Company, Kirby Building Systems and CBC Steel Buildings. In total, the Nucor Buildings Group currently has nine metal buildings plants with an annual capacity of approximately 360,000 tons, as well as an existing TrueCore facility in South Carolina and a second facility under construction in Indiana.

About Nucor

Nucor and its affiliates are manufacturers of steel and steel products, with operating facilities in the United States, Canada and Mexico. Products produced include: carbon and alloy steel — in bars, beams, sheet and plate; hollow structural section tubing; electrical conduit; steel piling; steel joists and joist girders; steel deck; fabricated concrete reinforcing steel; cold finished steel; precision castings; steel fasteners; metal building systems; steel grating; and wire and wire mesh. Nucor, through The David J. Joseph Company, also brokers ferrous and nonferrous metals, pig iron and hot briquetted iron / direct reduced iron; supplies ferro-alloys; and processes ferrous and nonferrous scrap. Nucor is North America’s largest recycler.

View original content:http://www.prnewswire.com/news-releases/nucor-announces-plans-to-build-truecore-facility-in-utah-301234625.html

SOURCE Nucor Corporation

NEW YORK, Feb. 24, 2021 /PRNewswire/ — Wolf Haldenstein Adler Freeman & Herz LLP  reminds all investors that a federal securities class action lawsuit was filed in the United States District Court for the Central District of California against Decision Diagnostics Corp. (“Decision Diagnostics” or “the Company”) (OTCBB: DECN) on behalf of investors who purchased the Company’s securities between March 3, 2020 and December 17, 2020, inclusive (the ”Class Period”).

All
investors who purchased shares
of Decision Diagnostics Corp. and incurred losses are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action or join the caseon our website, www.whafh.com.

If   you have incurred losses in  the  shares of Decision Diagnostics Corp., you may,no later than March 16, 2021,  request that the Court appoint you lead plaintiff of the proposed class.  Please contact Wolf Haldenstein to learn more about your rights as an investor in the shares of Decision Diagnostics Corp.

CLICK HERE TO JOIN CASE

According to the filed Complaint, the Company made false and misleading statements to the market. Decision Diagnostics failed to develop a viable COVID-19 test in any form, let alone a test that could detect the virus in less than one minute. The Company was not capable of meeting the U.S. Food and Drug Administration’s (FDA’s) EUA testing requirements for its purported COVID-19 test. Despite this inability to meet FDA requirements, the Company touted an unrealistic time to market for its tests. Based on these facts, the Company’s public statements were false and materially misleading throughout the class.

Wolf Haldenstein
has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas, and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at  www.whafh.com.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected] 
Tel: (800) 575-0735 or (212) 545-4774

View original content:http://www.prnewswire.com/news-releases/decision-diagnostics-corp-class-action-alert-wolf-haldenstein-adler-freeman–herz-llp–reminds-investors-that-a-federal-securities-class-action-lawsuit-has-been-filed-against-decision-diagnostics-corp-301234297.html

SOURCE Wolf Haldenstein Adler Freeman & Herz LLP

SAN DIEGO, Feb. 24, 2021 /PRNewswire/ — Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day to be held today, February 24, 2021 beginning at 10am ET.

“Over the past year, we have made tremendous progress as we continue to validate our novel technology platforms and advance our broad and deep clinical and preclinical programs,” commented Eric Ostertag, M.D., Ph.D., Chief Executive Officer. “During today’s R&D Day, we will take a deep dive into Poseida’s novel cell and genetic engineering platform technologies, differentiated CAR-T programs and innovative approaches to cell and gene therapy. We look forward to highlighting our progress to date, introducing a new potential pipeline product candidate, as well as several emerging discovery programs, and discussing our corporate strategy.”

Specific highlights will include an early look at the ongoing P-PSMA-101 clinical trial; demonstration of the potential for single treatment cures with a completely non-viral nanoparticle-based gene therapy system; an extensive study of our Cas-CLOVER™ Site-Specific Gene Editing System demonstrating best-in-class gene editing specificity; and a look at our CAR-NK, and induced pluripotent stem cell, or iPSC, capabilities.

Key Program Highlights

Autologous CAR-T Update
P-BCMA-101 is an autologous CAR-T product candidate in an ongoing Phase 1 dose expansion trial and Phase 2 trial in development for the treatment of relapsed/refractory multiple myeloma to treat patients with multiple myeloma. Today’s discussion will include data demonstrating the importance of T stem cell memory in CAR-T. The Company intends to provide an update on this program later in 2021.

P-PSMA-101 is a solid tumor autologous CAR-T product candidate in an ongoing Phase 1 dose escalation trial in development to treat patients with metastatic castrate resistant prostate cancer, or mCRPC. Today’s presentation will include a case study of a patient with mCRPC treated with P-PSMA-101 at a dose of 0.25 x 10e6 cells/kg (~20 x 10e6 total cells) who showed a marked decrease in PSA expression levels of more than 50% in the first three weeks post treatment and is continuing on trial. The patient was reported to have Grade 1 CRS in the second week which was treated to resolution. The Company intends to provide an additional update on this program later in 2021.

Allogeneic CAR-T Update (including Cas-CLOVER off-target analysis)
P-BCMA-ALLO1 is the Company’s first allogeneic CAR-T product candidate in development for the treatment of relapsed/refractory multiple myeloma. The Company will present updated preclinical data and ongoing IND enabling work, with an expected filing in the first half of 2021. Data utilizing Cas-CLOVER™, the Company’s high-precision gene editing technology to eliminate knock out TCR and B2M to address alloreactivity in P-BCMA-ALLO1, will also be presented. 

P-MUC1C-ALLO1 is the Company’s allogeneic CAR-T product candidate currently in preclinical development, with the potential to treat a wide range of solid tumors, including breast and ovarian cancers. The Company will share updated preclinical data demonstrating complete tumor elimination in triple negative breast and ovarian cancer models. P-MUC1C-ALLO1 will be the first clinical product to be manufactured at Poseida’s pilot manufacturing facility in San Diego, with an IND filing expected by the end of 2021.

piggyBac^® Delivery in vivo for Liver Directed Gene Therapies
P-OTC-101 is the Company’s first liver-directed gene therapy program for in vivo treatment of urea cycle disease caused by congenital mutations in the OTC gene, a condition characterized by high unmet medical need. Preclinical data from ongoing IND enabling studies will be presented by Bruce Scharschmidt, M.D., an expert in OTC deficiency and a consultant to Poseida.

Denise Sabatino, Ph.D., a recognized expert in Factor VIII therapy for Hemophilia, will present the Company’s piggyBac Factor VIII program for hemophilia A, P-FVIII-101, delivered by Poseida’s proprietary nanoparticle technology. Nanoparticle plus piggyBac delivery of Factor VIII demonstrates near normal levels of Factor VIII expression in juvenile mice with a single treatment in preclinical models.

Emerging Programs

TCR-T: Poseida’s TCR-T platform combines the Company’s piggyBac DNA delivery and Cas-CLOVER gene editing technologies in order to generate effective and functional off-the-shelf TCR-T product candidates with a high percentage of highly desirable Tscm cells. The TCR-T platform could be leveraged to increase the number of potential indications in oncology and beyond, including infectious diseases and autoimmunity.

Anti-cKit CAR-T: Safer non-genotoxic conditioning regimens are potentially possible with the Company’s anti-cKit CAR-T program for hematopoietic stem cell, or HSC, conditioning, which may reduce transplant morbidity and mortality, resulting in better outcomes and a greatly expanded number of potential indications. Data include results from preclinical experiments demonstrating the ability of anti-cKit CAR-T cells to deplete human stem cell grafts in NSG mice and to prolong survival in a mouse model of AML.

Genetically Modified HSCs: HSCs can be modified via the piggyBac DNA Delivery System and/or the Cas-CLOVER Site-Specific Gene Editing System. Today’s presentation will show data confirming that genetically modified HSCs engraft in the bone marrow and demonstrate long-term persistence. CAR-HSC has the potential to be a highly effective CAR-T approach, as it theoretically could provide an inexhaustible supply of effector cells to eradicate tumor and can be differentiated to generate high yields of CAR-T, CAR-NK and CAR-myeloid cells.

iPSCs: Cas-CLOVER is also efficient for creating knockouts and knock-ins in induced pluripotent stem cells, or iPSCs, with very low toxicity. Data will be presented showing the greater efficiencies of Cas-CLOVER as compared to an industry standard editing platform for therapeutic knock-in using plasmid DNA.

Genetically Modified NK Cells: The Company will also present data on efficient genetic modification of NK Cells using piggyBac and Cas-CLOVER platform technologies. The Cas-CLOVER gene editing system can be used to efficiently edit NK cells, or CAR-NK cells, while piggyBac can be used to effectively deliver large therapeutic transgenes to activated or un-activated peripheral blood NK cells which maintain CAR expression, phenotype, and function. Several emerging potential CAR-NK cell product candidates will be revealed, all of which demonstrate specific killing of cancer cells.

R&D Day Webcast Information
A live webcast of the Company’s R&D Day event will be available on the Investors & Media section of Poseida’s website, www.poseida.com. A replay of the webcast will be available for 30 days following the presentation.

About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac DNA Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. To learn more, visit www.poseida.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding the clinical data presented, the potential benefits of Poseida’s technology platforms and product candidates and Poseida’s plans and strategy with respect to developing its technologies and product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Poseida’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry, the fact that future clinical results could be inconsistent with results observed to date and the other risks described in Poseida’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Poseida undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/poseida-therapeutics-provides-update-on-key-programs-and-developments-during-rd-day-301234115.html

SOURCE Poseida Therapeutics, Inc.

BETHESDA, Md., Feb. 24, 2021 /PRNewswire/ — The J. Willard and Alice S. Marriott Foundation together with Howard University announced today the establishment of the Marriott-Sorenson Center for Hospitality Leadership in honor of Marriott International’s (NASDAQ: MAR) beloved president and CEO, Arne Sorenson, who tragically passed away last week from pancreatic cancer. The J. Willard and Alice S. Marriott Foundation will provide a $20 million endowment to launch the Center at Howard University, one of the nation’s leading historically Black colleges and universities.

In addition, Marriott International announced the creation of the Arne M. Sorenson Hospitality Fund which will support the critical programmatic and career development elements of the Center. This Fund is dedicated to helping the industry build leadership talent in hospitality. Marriott has pledged the first donation of $1 million and is inviting other companies, organizations and individuals – from all industries – to support this effort.

The Marriott-Sorenson Center for Hospitality Leadership, which will be housed in Howard University’s School of Business, will feature a best-in-class program that expands educational and professional opportunities for Howard students and aims to develop future executives in the hospitality industry.

“I can think of no better tribute to the amazing legacy of Arne Sorenson than to focus on educating and advancing future leaders of the hospitality industry,” said J.W. “Bill” Marriott, Jr., Executive Chairman and Chairman of the Board, Marriott International. “Arne’s passion for creating a culture of opportunity brought real change in the executive ranks of our company. But work remains to be done. Our industry needs a pipeline of diverse leadership talent and that’s exactly what this Center will achieve. We are proud to bring Marriott International and our family foundation together to partner with this esteemed university in the city of our founding. This innovative program will foster leadership excellence and help drive greater inclusion at the most senior levels of the hospitality industry. We hope that other hospitality companies will join us in designing the program and providing experiential opportunities to generate talent that will meet the needs of the industry well into the future.”  

“Now is the opportune time to launch this work,” said Mieka Wick, Executive Director, The J. Willard and Alice S. Marriott Foundation. “The hospitality industry is evolving in new and exciting ways and there is a clear need for a forward-looking program designed to prepare leaders for this dynamic environment. A deeper commitment to diversity, equity and inclusion is imperative, not only because it is the right thing to do but because it is also good for the industry. The J. Willard and Alice S. Marriott Foundation has a long-standing commitment to creating opportunity for all in the hospitality industry. Howard University, one of the nation’s finest historically Black colleges and universities, is ideally suited to partner with us, given the extraordinary students it serves.”

“Lack of diversity in the executive ranks of companies across America has long been a headline and has been further elevated in the national conversation as we are in this important moment of racial reckoning,” said Dr. Wayne A. I. Frederick, President, Howard University. “Through this partnership with The J. Willard and Alice S. Marriott Foundation and Marriott International, we are best positioned to further our existing commitment and address this most pressing issue. As I have gotten to know the Marriott family over the years, I have been impressed with their commitment to the community and excellence. This program will be a game changer for Howard University students and the hospitality industry by designing unique educational opportunities that meet the future demands of the industry, shaping the already promising talents and passions of our business students, and connecting those students with meaningful careers in the industry. What we are creating is a direct connection between an industry that is on the edge of change and a top caliber talent pool for them to recruit from,” Dr. Frederick said.

World-class Hospitality Curriculum

Today’s announcement establishes the Marriott-Sorenson Center for Hospitality Leadership as well as the Arne M. Sorenson Hospitality Fund, which will support the programmatic and career development elements of the Center. The experiential components of this new program, including access to top hospitality executives and industry leaders for Howard students, will make this curriculum appealing and unique. The Marriott family foundation and Howard University will work together to form a hospitality industry advisory council to design a program that will draw on the university’s ideal location in the geographic heart of the hospitality industry—Greater Washington, D.C.—where Marriott and many other hospitality companies are headquartered. In addition to advising on the development of a world-class hospitality curriculum, the Center’s advisory council members will serve as guest lecturers and mentors and provide hands-on learning opportunities for students. The council will include representatives from Howard, the Marriott family foundation and Marriott International as well as corporate hospitality executives, industry practitioners, association leaders and academics who together will develop a hospitality program focused on traditional and experiential learning opportunities. The goal will be to expose students to the hospitality industry through a management lens.

To learn more about the Marriott-Sorenson Center for Hospitality Leadership and the Arne M. Sorenson Hospitality Fund, or to make a donation, please visit www.howard.edu/sorensonfund. To make a major gift, please contact: Dawn Ridley, Assistant Vice President, Institutional Giving via phone or email at (202) 238-2350 or [email protected].

About Arne Sorenson

Arne M. Sorenson was President and Chief Executive Officer of Marriott International, Inc., from 2012 until his passing in February 2021. In his role, he presided over the world’s largest hospitality company and some of the most iconic brands in travel. Mr. Sorenson built his tenure on the bedrock of Marriott International’s core values: putting people first, pursuing excellence, acting with integrity, embracing change and serving our world.

Mr. Sorenson led the acquisition of Starwood Hotels & Resorts Worldwide in 2016, resulting in a dramatic expansion of Marriott’s ability to provide unparalleled guest experiences around the world. The company now has more than 7,600 properties across 133 countries and territories and 30 brands. The merger also created the travel industry’s largest customer-loyalty program, Marriott Bonvoy, which has more than 147 million members.

An outspoken corporate leader, Mr. Sorenson advocated for environmental sustainability, human rights, and diversity, equity and inclusion. Under his leadership, Marriott International was recognized extensively, including by Fortune in 2020 as one of the World’s Most Admired Companies and DiversityInc as one of the Top 50 Companies for Diversity. In 2019, Mr. Sorenson was named CEO of the Year by Chief Executive magazine and was placed on Forbes’ list of America’s Most Innovative Leaders and Barron’s list of the World’s Best CEOs.

About Marriott International
Marriott International, Inc. (NASDAQ: MAR) is based in Bethesda, Maryland, USA, and encompasses a portfolio of more than 7,600 properties under 30 leading brands spanning 133 countries and territories. Marriott operates and franchises hotels and licenses vacation ownership resorts all around the world. The company offers Marriott Bonvoy™, its highly– awarded travel program. For more information, please visit our website at www.marriott.com, and for the latest company news, visit www.marriottnewscenter.com.

About Howard University
Founded in 1867, Howard University is a private, research university that is comprised of 13 schools and colleges. Students pursue more than 140 programs of study leading to undergraduate, graduate and professional degrees. The University operates with a commitment to Excellence in Truth and Service and has produced one Schwarzman Scholar, three Marshall Scholars, four Rhodes Scholars, 11 Truman Scholars, 25 Pickering Fellows and more than 165 Fulbright recipients.  Howard also produces more on-campus African American Ph.D. recipients than any other university in the United States. For more information on Howard University visit www.howard.edu.

About The J. Willard and Alice S. Marriott Foundation
The J. Willard and Alice S. Marriott Foundation works to create access and expand opportunities in communities by partnering with non-profit organizations committed to solving today’s challenges and improving the lives of others in service of vibrant and thriving communities. Founded in 1966, the Foundation invests to strengthen the vitality of the Washington, D.C. community and surrounding region, advance disease-specific therapeutics and mental health initiatives, and promote career preparedness, with a focus in the hospitality industry. The Foundation embraces collaborative relationships with its partners across industries and sectors to drive the greatest impact. Active engagement as a leader and collaborator in the community, both listening to the community’s voice and promoting their interests, is a long-held, valued practice of the Marriott family and the Foundation. To learn more about The J. Willard and Alice S. Marriott Foundation, please visit https://www.marriottfoundation.org/

View original content to download multimedia:http://www.prnewswire.com/news-releases/the-j-willard-and-alice-s-marriott-foundation-announces-20-million-endowment-at-howard-university-to-establish-the-marriott-sorenson-center-for-hospitality-leadership-301234624.html

SOURCE Marriott International, Inc.

NEW YORK, Feb. 24, 2021 /PRNewswire/ — Reonomy, a leading provider of actionable CRE insights, today announced that JPMorgan Chase will harness Reonomy ID and the Reonomy Knowledge Graph to enhance its property data strategy. The ID, a unique identifier for each commercial real estate asset, will enable the firm to easily fuse disparate property datasets together, while the Knowledge Graph will help to augment their property data. Collectively, the technology will enable JPMorgan Chase to deliver timely information, powerful analytics and deeper insights to their CRE clients.

The Reonomy platform is comprised of a web application and data solutions built on unified technology and data standards. The platform connects disparate property information through machine learning and the proprietary Knowledge Graph providing in-depth property intelligence on commercial properties, transactions, and companies for a variety of organizations.

“We’re committed to bringing value to our CRE clients, and providing them with the best available data – comprehensive, up-to-date and accurate – is essential to delivering that value,” said Steve Turk, Chief Data & Analytics Officer for the Commercial Banking business at JPMorgan Chase. “We’re excited to work with Reonomy and to help our clients access new data-driven insights and opportunities.”

“As one of our first clients, JPMorgan Chase has played an enormous role in our development and they’ve been a great partner for many years,” said Reonomy CEO, Bill Okun. “Working with them gives us the opportunity to provide more property intelligence to the industry at-large.”

This strategic relationship with Reonomy is part of JPMorgan Chase’s firmwide commitment to collaborate with fintech and proptech companies to help craft the best business solutions for clients.

About Reonomy:

Reonomy is the leading provider of CRE insights, empowering top brokerages, financial institutions, and commercial services providers with actionable data and solutions. Armed with Reonomy’s enterprise-grade products, CRE professionals and organizations gain comprehensive market understanding, discover opportunities, and streamline research processes. For more information, visit https://www.reonomy.com or follow us @Reonomy on Twitter.

About JPMC Commercial Banking:

JPMorgan Chase Commercial Banking is a business of JPMorgan Chase & Co. (NYSE: JPM), a leading global financial services firm with assets of $3.4 trillion and operations worldwide. Through its Middle Market Banking & Specialized Industries, Corporate Client Banking & Specialized Industries and Commercial Real Estate businesses, Commercial Banking serves emerging startups to midsize businesses and large corporations as well as government entities, not-for-profit organizations, and commercial real estate investors, developers and owners. Clients are supported through every stage of growth with specialized industry expertise and tailored financial solutions including credit and financing, treasury and payment services, international banking and more. Information about JPMorgan Chase Commercial Banking is available at www.jpmorganchase.com/commercial.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/jpmorgan-chase-collaborates-with-reonomy-to-deliver-data-and-insights-to-power-the-commercial-real-estate-industry-301234275.html

SOURCE Reonomy

HUNTINGTON, W.Va., Feb. 24, 2021 /PRNewswire/ — PREMIER FINANCIAL BANCORP, INC. (PREMIER) (NASDAQ/GMS: PFBI) a $1.9 billion financial holding company with two community bank subsidiaries announced today that it will pay a first quarter cash dividend of $0.15 per share on its common stock.  At its regularly scheduled February meeting, the board of directors declared a $0.15 per share dividend to common shareholders of record on March 15, 2021. The cash dividend will be paid to shareholders on March 31, 2021.

Certain Statements contained in this news release, including without limitation, statements including the word “believes,” “anticipates,” “intends,” “expects” or words of similar import, constitute “forward-looking statements” within the meaning of section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Premier to be materially different from any future results, performance or achievements of Premier expressed or implied by such forward-looking statements.  Such factors include, among others, general economic and business conditions, changes in business strategy or development plans and other factors referenced in this press release.  Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements.  Premier disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.

View original content:http://www.prnewswire.com/news-releases/premier-financial-bancorp-inc-announces-first-quarter-dividend-301234087.html

SOURCE Premier Financial Bancorp, Inc.

NEW YORK, Feb. 24, 2021 /PRNewswire/ — Roundhill Investments, an ETF sponsor focused on offering innovative thematic funds, has announced that the firm has invested a portion of its liquid assets into its own funds, including NERD – The Esports ETF,  BETZ – The Sports Betting ETF, and SUBZ – The Streaming ETF.

Roundhill Co-Founder Will Hershey commented: “Our new treasury policy allows for us to invest alongside our ETF shareholders in three themes we truly believe in, esports, sports betting, and streaming. We plan to take a similar approach for future fund launches, several of which we have planned for 2021.”

Roundhill has opted to open the firm’s brokerage account on Public.

To learn more about the funds, please visit roundhillinvestments.com/etf.

About Roundhill Investments
Roundhill Investments is a registered investment adviser and ETF sponsor focused on thematic and sector-specific investing. We create thoughtful investment products designed to help investors express their vision of the future. To learn more about the company, please visit roundhillinvestments.com.

Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus or summary prospectus with this and other information about Roundhill ETFs please visit the website at https://www.roundhillinvestments.com. Read the prospectus or summary prospectus carefully before investing.

These include risks related to investments in small and mid-capitalization companies, which may be more volatile and less liquid due to limited resources or product lines and more sensitive to economic factors. Funds investments may be non-diversified, meaning its assets may be concentrated in fewer individual holdings than a diversified fund and, therefore, more exposed to individual stock volatility than diversified funds. Investments in foreign securities involves social and political instability, market illiquidity, exchange-rate fluctuation, high volatility and limited regulation risks. Emerging markets involve different and greater risks, as they are smaller, less liquid and more volatile than more develop countries. Depositary Receipts involve risks similar to those associated with investments in foreign securities, but may not provide a return that corresponds precisely with that of the underlying shares. All investing involves risk, including possible loss of principal. Please see the prospectus for specific risks related to each fund.

Roundhill Investments and Foreside are not affiliated with Public.

Shares are bought and sold at market price not net asset value (NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns.

Roundhill Financial Inc serves as the investment advisor. The Funds are distributed by Foreside Fund Services, LLC which is not affiliated with Roundhill Financial Inc, U.S. Bank or any of their affiliates.

View original content:http://www.prnewswire.com/news-releases/roundhill-investments-invests-treasury-assets-in-roundhill-etfs-301233861.html

SOURCE Roundhill Investments

ATLANTA, Feb. 24, 2021 /PRNewswire/ — Invesco Ltd. (NYSE: IVZ), a leading global asset management firm, today announced the launch of the Invesco International Developed Dynamic Multifactor ETF (IMFL). The addition of IMFL broadens the firm’s dynamic multifactor suite, which currently includes ETFs that access large-cap and small-cap US equities to include international equities. Invesco’s dynamic multifactor ETFs adapt and evolve factor holdings as the market environment changes.

“Invesco has a strong track record of offering dynamic multi-factor ETFs that adapt and evolve factor holdings as the market environment changes,” said Anna Paglia, Global Head of ETFs and Indexed Strategies at Invesco. “Clients will now have access to international equities across geographies through an easily accessible single suite of ETFs.”

IMFL seeks to track the investment results of the FTSE Developed ex US Invesco Dynamic Multifactor Index¹, a rules-based index that re-weights securities to align rewarded factors according to economic cycles and overall market conditions. Factor exposures are targeted according to the four stages of the business cycle; recovery, expansion, slowdown and contraction. IMFL’s underlying index is powered by a proprietary methodology for identifying economic and market sentiment indicators, which leverages intellectual capital of Invesco Investment Solutions in partnership with Invesco’s indexing business. IMFL and its index are reconstituted and rebalanced as frequently as monthly.

The FTSE Developed ex US Index, the parent index of the FTSE Developed ex US Invesco Dynamic Multifactor Index, is comprised of large-capitalization (85%) and mid-capitalization (15%) stocks of companies located in 24 developed market countries around the world, excluding the United States.

Other ETFs included in the dynamic multifactor suite are Invesco Russell 1000 Dynamic Multifactor ETF (OMFL) with a 5-star Morningstar Overall rating out of 1230 funds in the Large Blend Category and the Invesco Russell 2000 Dynamic Multifactor ETF (OMFS), with 5-star Morningstar Overall rating out of 630 funds in the Small Blend Category. Morningstar ratings are based on risk adjusted return as of Jan. 31, 2021^2. These funds also leverage the same intellectual capital of the Invesco Investment Solutions team.

About Invesco Ltd.
Invesco Ltd. (Ticker NYSE: IVZ) is a global independent investment management firm dedicated to delivering an investment experience that helps people get more out of life. Our distinctive investment teams deliver a comprehensive range of active, passive and alternative investment capabilities. With offices in more than 20 countries, Invesco managed US$1.35 trillion in assets on behalf of clients worldwide as of December 31, 2020.  For more information, visit www.invesco.com/corporate.

About FTSE Russell:
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.  FTSE Russell is wholly owned by London Stock Exchange Group.  For more information, visit www.ftserussell.com.

¹ Index returns do not represent Fund returns. An investor cannot invest directly in an index.
² OMFL received 5 stars for the overall and three years, N/A stars for the five years and N/A stars for the 10 years. The fund was rated among 1230, 1230, N/A, N/A funds within the Morningstar Large Blend Category of the overall period, three, five and 10 years, respectively. OMFS received 5 stars for the overall and three years, N/A stars for the five years and N/A stars for the 10 years. The fund was rated among 630, 630, N/A, N/A funds within the Morningstar Large Blend Category of the overall period, three, five and 10 years, respectively. Morningstar ratings are as of Jan. 31, 2021,
Morningstar ratings are based on a risk-adjusted return measure that accounts for variation in a fund’s monthly performance, placing more emphasis on the downward variations and rewarding consistent performance. Open-end mutual funds and exchange-traded funds are considered a single population for comparison purposes. Ratings are calculated for funds with at least a three year history. The overall rating is derived from a weighted average of three-, five- and 10-year rating metrics, as applicable, excluding sales charges and including fees and expenses. Had fees not been waived and/or expenses reimbursed currently or in the past, the Morningstar rating would have been lower. The top 10% of funds in a category receive five stars, the next 22.5% four stars, the next 35% three stars, the next 22.5% two stars and the bottom 10% one star. Ratings for other share classes may differ due to different performance characteristics.
©2019 Morningstar, Inc. All rights reserved. The information contained herein is proprietary to Morningstar and/or its content providers. It may not be copied or distributed and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance cannot guarantee comparable future results.

About Risk
There are risks involved with investing in ETFs, including possible loss of money. Shares are not actively managed and are subject to risks similar to those of stocks, including those regarding short selling and margin maintenance requirements. Ordinary brokerage commissions apply. The Fund’s return may not match the return of the Underlying Index. The Fund is subject to certain other risks. Please see the current prospectus for more information regarding the risk associated with an investment in the Fund.

Investments focused in a particular industry or sector are subject to greater risk, and are more greatly impacted by market volatility, than more diversified investments.

The risks of investing in securities of foreign issuers can include fluctuations in foreign currencies, political and economic instability, and foreign taxation issues.

The performance of an investment concentrated in issuers of a certain region or country, such as the Japan and the European Union, is expected to be closely tied to conditions within that region and to be more volatile than more geographically diversified investments.

Stocks of medium-sized companies tend to be more vulnerable to adverse developments, may be more volatile, and may be illiquid or restricted as to resale.

Momentum style of investing is subject to the risk that the securities may be more volatile than the market as a whole or returns on securities that have previously exhibited price momentum are less than returns on other styles of investing.

The Fund is non-diversified and may experience greater volatility than a more diversified investment.

The Fund may engage in frequent trading of its portfolio securities in connection with the rebalancing or adjustment of the Underlying Index.

A value style of investing is subject to the risk that the valuations never improve or that the returns will trail other styles of investing or the overall stock markets.

FTSE International Limited. FTSE® is a trademark of the London Stock Exchange Group plc and its group undertakings and is used by FTSE under license. FTSE has been licensed for use in the Underlying Index by the Adviser. The Fund is not in any way sponsored, endorsed, sold or promoted by FTSE, Frank Russell Company, or the London Stock Exchange Group companies (“LSEG”) (together the “Licensor Parties”) and none of the Licensor Parties make any claim, prediction, warranty or representation whatsoever, expressly or impliedly, either as to (i) the results to be obtained from the use of the Underlying Index, (ii) the figure at which the Underlying Index is said to stand at any particular time on any particular day or otherwise, or (iii) the suitability of the Underlying Index for the purpose to which it is being put in connection with the Fund. None of the Licensor Parties have provided or will provide any financial or investment advice or recommendation in relation to the Underlying Index to the Adviser or to its clients. The Underlying Index is calculated by FTSE or its agent. None of the Licensor Parties shall be (a) liable (whether in negligence or otherwise) to any person for any error in the Underlying Index or (b) under any obligation to advise any person of any error therein.

Shares are not individually redeemable and owners of the Shares may acquire those Shares from the Fund and tender those Shares for redemption to the Fund in Creation Unit aggregations only, typically consisting of 10,000, 25,000, 50,000, 75,000, 80,000, 100,000, 150,000 or 200,000 Shares.

Before investing, investors should carefully read the prospectus and/or summary prospectus and carefully consider the investment objectives, risks, charges and expenses. For this and more complete information about the fund(s), investors should ask their advisors for a prospectus/summary prospectus or visit invesco.com/fundprospectus.

Contact: Stephanie Diiorio, [email protected], 212.278.9037

View original content to download multimedia:http://www.prnewswire.com/news-releases/invesco-expands-dynamic-multi-factor-suite-with-international-equities-etf-301233641.html

SOURCE Invesco Ltd.

NORFOLK COUNTY, ON, Feb. 24, 2021 /PRNewswire/ – Target Group Inc. (OTCQB: CBDY) is pleased to announce that its wholly owned subsidiary, Canary Rx Inc. (“Canary” or the “Company”) has completed its first three (3) B2B wholesale cannabis transactions through its strategic joint-venture, Venn Cannabis, marking the beginning of a promising future for the company.

Canary RX, through its joint venture partnership, Venn Cannabis, has been working meticulously to ensure production of ultra-premium, craft cannabis in its Simcoe, Ontario production facility, enabling delivery of its unique genetic offerings and providing a strong platform for other retail brands in the market to build a portfolio of whole flower consumer products. The company is currently in discussions with several additional licenced producers and is very optimistic that over the next year, can establish itself as a leader in contract-based craft cultivation at scale within the Canadian cannabis landscape.

“These transactions represent several strategic revenue opportunities for Target Group through potential partnerships and long-term supply agreements and builds Canary Rx’s Canadian wholesale operations,” said Tony Zarcone, CEO of Target Group.

About Canary Rx Inc.
Canary Rx Inc. (“Canary”) is a Licensed Producer under the Cannabis Act. Situated in Ontario’s Garden, Norfolk County, Canary lies nestled amongst the shores of Lake Erie in a vibrant, agricultural community. Our 44,000 sq. ft. facility is engineered to meet strict quality standards and equipped with the latest environmental control technology. The production space includes eight separate flower rooms, projected to produce up to 4,500kg cannabis per year. Canary’s talented team will cultivate premium, craft cannabis, while aligning with distinguished, veteran brands to bring the highest quality product to market. www.canaryrx.com

About Target Group Inc. (CBDY) –
 Target Group Inc. (“Target Group” or the “Company”) is a progressive, diversified, and vertically integrated cannabis acquisition company. Target Group is curating an iconic brand portfolio, leveraging product diversification, innovation, and operational expertise to solidify long-term growth and stability. The Company owns and operates Canary RX Inc, a Health Canada licensed producer under The Cannabis Act (Bill C-45), and CannaKorp, makers of the pod-based Wisp™ Vapor technology. Target Group is expanding its global operations to build an international network of manufacturing, distribution, production, and sales operations. www.targetgroupinc.ca  

Forward-Looking Statements Disclaimer:
 This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.

View original content to download multimedia:http://www.prnewswire.com/news-releases/canary-rx-inc-completes-its-first-3-wholesale-transactions-of-its-cannabis-to-multiple-canadian-licensed-producers-301234600.html

SOURCE Target Group Inc.

SCOTTSDALE, Ariz., Feb. 24, 2021 /PRNewswire/ — GoDaddy Inc. (NYSE: GDDY), the company that empowers everyday entrepreneurs, today announced a plugin bundle expansion for its Managed WordPress Ecommerce customers, featuring free access to a library of over 75 premium WooCommerce extensions. The new extensions come from GoDaddy’s recent acquisition of SkyVerge, a leading WooCommerce product developer.

The new extensions, combined with a vast library of WordPress plugins and themes, give web designers and developers greater flexibility and infinite possibility to create fully featured and customized WooCommerce stores for their clients. The extensions increase the value of GoDaddy’s WooCommerce plugins from $3,000 to nearly $6,000 worth of premium extensions -available for free for GoDaddy’s Managed WordPress Ecommerce customers. New plugins include the ability to accept payments from multiple processors, improvements to product reviews, social login integrations, Google Analytics Pro and Memberships, new digital or printable gift card offerings, and more.

“The additional premium WooCommerce extensions make it so much easier for me to build fully customizable and powerful Ecommerce stores for my clients,” said GoDaddy customer Phaedra Poliquin, co-creator of Letsrethinkthis.com. “This type of functionality would have easily cost hundreds or even thousands annually, allowing me to save money, grow my business, and dedicate my time to helping my clients make the most out of their online stores.”

GoDaddy is also introducing a new seamless experience and site construction flow for Managed WordPress Ecommerce customers to quickly build powerful online stores for their clients. Website designers and developers can now get their clients’ online stores up and running in fewer steps. The plan includes a new built-in support dashboard, daily backups with one-click restore and daily malware scans and repair, including security activity auditing, remote malware scanning, and security notifications with guaranteed clean-up of any malware found on a client’s site.

“As more businesses move online, it is important for website designers and developers to have the right tools in place to create impactful online stores for their clients,” said Patrick Pulvermuller, President of Partners Business at GoDaddy. “With this launch, we’re thrilled to offer our customers even more functionality with WooCommerce, the world’s most popular open-source ECommerce solution, along with the strength and versatility of WordPress which powers over one third of websites online today.”

To provide the best and tailored experience for GoDaddy Managed WordPress Ecommerce customers, GoDaddy is also launching a new support message center directly into the WordPress platform to centralize support and care. Customers can now get in touch with expert WordPress and WooCommerce GoDaddy specialists to address any questions any time.

Learn more about GoDaddy Managed WordPress Ecommerce here.

About GoDaddy
GoDaddy is empowering everyday entrepreneurs around the world by providing all of the help and tools to succeed online. GoDaddy is the place people come to name their idea, build a professional website, attract customers, sell their products and services, and manage their work. Our mission is to give our customers the tools, insights and the people to transform their ideas and personal initiative into success. To learn more about the company, visit www.GoDaddy.com.

Source: GoDaddy Inc.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/godaddy-launches-new-woocommerce-extensions-for-managed-wordpress-ecommerce-hosting-301233838.html

SOURCE GoDaddy